Weight-loss drugs are forcing employers to redesign health benefits

Employer-sponsored healthcare costs will rise 7.9% in 2026 to $8,460 per average person, or $37,824 for a family of four, the largest non-COVID jump in more than a decade. The single fastest-growing cost component is pharmacy, up 14.8% year over year, and GLP-1 agonists, the drug class behind Ozempic and Wegovy, are the category Milliman cites as a meaningful driver of that growth. That pressure is forcing the largest U.S. buyers of commercial coverage to redesign benefits around a drug class that works but costs too much, pushing workers onto direct-to-consumer pharmacy channels, FSA and HSA dollars, and tighter prior authorization rather than absorbing the sticker price inside traditional plan design.

The IFEBP's June 2026 Pulse Survey of roughly 300 U.S. employer health plans shows how the bill lands on the formulary. GLP-1s accounted for 11.4% of annual claims in 2026, up from 6.9% in 2023. Sixty percent of plans now cover GLP-1s for diabetes only, up from 55% in 2025, and only 36% cover the drugs for both diabetes and weight loss, essentially flat with last year. About 45% of plans cover the drugs for other approved indications, including obstructive sleep apnea and heart disease, an expanding footprint that lets plan designers route approvals around the politically charged weight-loss label. IFEBP 2026 Pulse Survey findings, reported by CNBC.

The Business Group on Health's 2026 large-employer survey, fielded across more than 100 companies, frames the response. Roughly eight in ten employers say GLP-1s are driving up healthcare costs. Sixty-seven percent cover the drugs for weight management, and 72% of those expect to maintain coverage next year; only about 10% expect to drop it. Eighty-three percent use standard cost-sharing rather than special benefit designs, and 87% expect demand to rise as oral GLP-1s reach the market; only 9% expect prices to fall. Business Group on Health 2026 survey, reported by HealthcareDive.

Milliman's 2026 Medical Index makes the macro pressure concrete. Pharmacy is up 14.8% year over year, the fastest of any cost component, and outpatient facility care plus pharmacy together explain 69% of the year-over-year rise. The 7.9% MMI increase, the largest non-COVID jump in the index's history, is the figure that gets quoted in boardrooms. Milliman 2026 Medical Index.

So the redesign is not a coverage retreat. It is a channel shift.

The clearest mechanism is direct-to-consumer pharmacy. About 27% of IFEBP-surveyed plans now steer employees toward DTC platforms, where cash-pay pricing can undercut the insurance-benefit price and the employer is no longer the first payer. Another 21% push workers to FSA, HSA, or integrated HRA dollars, which shifts the marginal cost from the plan to the worker's pretax balance. Together, those two levers cover nearly half the plans in the IFEBP sample. Prior authorization has tightened in parallel, and formulary exclusions, particularly for weight-loss-only use, are the lever employers reach for when they want to preserve coverage for diabetes and cardiovascular indications while excluding cosmetic or lifestyle use.

In September 2025, a federal class action in D.C. (Hamburger v. CVS Caremark et al., Case No. 1:25-cv-03000) accused CVS Caremark and CareFirst BlueCross BlueShield of wrongfully denying Zepbound coverage for obstructive sleep apnea, the only FDA-approved prescription medication for that indication, in violation of plan terms and ERISA. The suit sits inside the same universe of pharmacy-benefit-coverage fights that has produced parallel compliance pressure on PBMs, including the Larkin v. Caremark ERISA line of cases. Hamburger v. CVS Caremark class action, via TopClassActions.

For workers, the practical read is this: a 2027 plan document that still lists Wegovy or Zepbound in the formulary may be doing less work than the headlines suggest. The coverage may be paired with prior-authorization hurdles, a DTC redirect, or an FSA-first design that pushes the cost onto pretax dollars the worker has already set aside. Employers are not abandoning the drug class; they are moving the line on who pays first, who pays next, and what counts as a covered medical need versus a benefit-design exclusion. The story STAT+ flagged this week, that GLP-1s are forcing employers to reconsider how they pay for workers' care, is the same story this data tells, only the headline verb is closer to "redesign" than "break."